IBI-110 is under clinical development by Innovent Biologics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IBI-110’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IBI-110 overview
IBI-110 is under development for the treatment of refractory solid tumors, advanced squamous non-small cell lung cancer, gastric cancer, non-small cell lung cancer, adenocarcinoma of the gastroesophageal junction, small-cell lung cancer, lymphoma and hepatocellular carcinoma (HCC) and esophageal squamous cell carcinoma. The drug candidate is administered by intravenous drip route and acts by targeting lymphocyte activation gene 3 protein (LAG3).
It was also under development for the treatment of metastatic cutaneous melanoma, diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, oral cavity, oropharyngeal, laryngeal and hypopharyngeal cancer.
Innovent Biologics overview
Innovent Biologics is a biopharmaceutical company that carries out the research, development and manufacturing of monoclonal antibodies. It provides products for therapeutic areas such as oncology, cardiovascular and metabolic diseases, autoimmune diseases, and ophthalmology. The company’s oncology products include sintilimab injection, bevacizumab injection, rituximab injection, pemigatinib, ramucirumab, and others. Innovent Biologics‘s autoimmune drugs are adalimumab injection, IBI-353, IBI-112 and IBI-314, among others. The company’s metabolic and ophthalmology products include IBI-306, IBI-362, IBI-302, IBI-324, IBI-311 IGF-1R and IBI-333, among others. It markets products under brands TYVYT, BYVASDA, SULINNO, HALPRYZA, Pemazyre, Cyramza, Retsevmo, FUCASO, and SINTBILO. The company operates in China, the US, the UK, Japan, Australia, Canada and Korea. Innovent Biologics is headquartered in Suzhou, Jiangsu, China.
For a complete picture of IBI-110’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
